Management of the post-bariatric surgery patient – what an internist needs to know

Gabriela Handzlik-Orlik¹, Michał T. Holecki¹, Leszek Kędzierski¹, Mariusz Wyleżoł², Jan Duława¹

¹Department of Internal Medicine and Metabolic Diseases, Medical University of Silesia, Katowice, Poland
²Department of Surgery, Military Institute of Aviation Medicine, Warsaw, Poland

Abstract

Bariatric surgery is the most effective method of achieving long-lasting weight loss and improving metabolic and cardiovascular outcomes in selected obese patients (i.e. with body mass index [BMI] ≥ 40 kg/m² without coexisting morbidities or BMI ≥ 35 kg/m² with severe obesity-related diseases). As the epidemic of obesity grows, it is estimated that by 2030 around 11% of the population will be severely obese. Therefore, the number of bariatric procedures performed increases year after year, and it reached 179,000 in 2013. Bariatric procedures can be divided into three main types: restrictive, malabsorptive, and mixed procedures. While, careful multi-disciplinary preoperative assessment of the patient is an inseparable part of bariatric procedures, there is also a need for multi-disciplinary management after bariatric surgery. This should include surveillance by an internist, surgeon and registered dietician. However, treatment outcome is primarily dependent on the patient’s compliance and awareness of the need for regular follow-up. This cannot be achieved without proper behavioral and psychological support, as it is as vital as other surveillance aspects. In this review we discuss early and late complications of bariatric surgery, its influence on obesity-related diseases, and changes in body composition and metabolism. According to recent guidelines and recommendations of American and European medical societies, we summarize available standards of post-bariatric management.

Key words: bariatric surgery, obesity, dumping syndrome, diabetes mellitus, lipid metabolism.

Introduction

Obesity is one of the most alarming health care problems worldwide, since around 2 billion adults are considered to be overweight (body mass index [BMI] between 25 and 30 kg/m²) or obese (BMI ≥ 30 kg/m²) [1]. The steadily growing prevalence of obesity is a matter of common concern, and forecasts predict that 11% of the population will be severely obese (BMI ≥ 40 kg/m²) by 2030 [2]. Overweight and obesity are major risk factors of chronic diseases, such as cardiovascular disease, type 2 diabetes mellitus (T2DM), some types of neoplasms and musculoskeletal disorders.

Non-surgical management of obesity is considered as a first line therapy, and it includes lifestyle changes (increased physical activity, modification of diet and behavior) and pharmacological treatment. It can induce mean weight losses of 5-10%. However, long-term weight loss maintenance is usually poor or insufficient. For patients who did not succeed in non-surgical intervention, but are at increased risk of obesity-related mortality and/or meet the criteria for surgery, a bariatric procedure may be considered.

The number of bariatric surgery procedures performed in the U.S. reached 173,000 in 2012, and 179,000 in 2013. This large group of patients will require lifelong, regular, qualified, multidisciplinary surveillance including medical, surgical, behavioral and dietary observation.

Bariatric surgery

Bariatric surgical techniques

Bariatric surgical procedures can be divided into three main types: restrictive, malabsorptive, and mixed procedures. Adjustable gastric banding and sleeve gas-
trectomy are predominantly restrictive procedures. They aim at reduction of oral intake by limiting gastric volume and production of early satiety; they leave the alimentary canal in continuity, minimizing the risk of metabolic complications. Bilio-pancreatic diversion as a malabsorptive procedure leads to reduction of stomach size and the physiological condition of malabsorption. Mixed procedures, such as gastric bypass and sleeve gastrectomy with duodenal switch, apply both techniques simultaneously [3].

The most commonly performed procedures are Roux-en-Y gastric bypass (RYGB), bilio-pancreatic diversion (BPD), sleeve gastrectomy (SG) and adjustable gastric banding (AGB) [4]. Bariatric surgery results in significant long-lasting weight loss, improves obesity-related co-morbidities and decreases mortality [5]. It must be mentioned that bariatric procedures (especially RYGB and SG) lead to gut hormone changes that may be implicated in these beneficial effects [6].

Indications for bariatric surgery

According to the guidelines of the National Institute of Clinical Excellence, the European Association for the Study of Obesity and the American Association of Clinical Endocrinologists, bariatric surgery should be considered in patients with:
- severe obesity (BMI ≥ 40 kg/m²) without coexisting obesity related disease,
- moderate obesity (BMI ≥ 35 kg/m²) with severe obesity related conditions such as type 2 diabetes mellitus, cardiovascular disease or obstructive sleep apnea [7,8].

Furthermore, patients with BMI of 30-34.9 kg/m² with T2DM and other obesity related diseases may also be offered a bariatric procedure, although evidence of long-term benefit in these patients is still limited.

Influence of bariatric surgery on obesity-related diseases

Compared to conventional treatment of obese patients, bariatric surgery is associated with a highest long-term reduction in all-cause mortality [9-11] and decreased prevalence and incidence of type 2 diabetes, myocardial infarction, stroke and cancer [12].

Type 2 diabetes mellitus

Recent emerging data on bariatric procedures indicate that bariatric surgery might be considered as metabolic surgery. This term refers to procedures intended to treatment of T2DM and to reduce cardiometabolic risk factors. According to the International Diabetes Federation, patients with BMI ≥ 35 kg/m² and T2DM who are inadequately controlled by lifestyle and medical therapy should be considered for bariatric surgery [9]. This statement is supported by a number of recent findings indicating significant benefits after a bariatric procedure in type 2 diabetic patients, including diabetes remission (albeit defined by varying criteria across different studies) in up to 72% of patients 2 years after surgery [12,13].

The remission of T2DM is observed within several days or weeks of the procedure, long before the reduction of body mass is noticeable. However, the improvement in metabolic condition may be transient, and within 3 years after surgery, 24% of patients who initially improve relapse into T2DM [14], and only 36% remain free of diabetes after 10 years [11]. Nevertheless, a long-term prospective controlled trial provided data confirming the efficacy of bariatric surgery on T2DM, with diabetes remission rates increased several-fold at 2 years (odds ratio OR = 8.42, p < 0.001) and 10 years (OR = 3.45, p < 0.001) [14] compared to conventional treatment.

Cardiovascular disease and hypertension

Obesity is associated with cardiomyopathy, left ventricular hypertrophy and diastolic dysfunction. Increased circulatory volume and cardiac output may also lead to the development of atrial dilatation and systolic dysfunction [4]. Bariatric procedures lead to a 50% lower incidence of fatal and total cardiovascular events (after adjustment for age and BMI) compared to non-surgical treatment [5]. Bariatric surgery beneficially modulates and reverses ventricular remodeling, improving both systolic and diastolic function [15]. The mechanisms are not fully elucidated, but improvements in hyperinsulinemia, dyslipidemia and hypertension are believed to facilitate the process. The mechanical weight loss effect and decreased inflammation may also be pivotal.

Initial improvements in hypertension and dyslipidemia may diminish with time; however, after 10 years of follow-up blood pressure and serum total cholesterol are still reduced compared to baseline values [16]. According to a systematic review and meta-analysis by Buchwald et al., 78.5% of patients show postoperative resolution or improvement of hypertension. Similarly, hyperlipidemia (particularly total cholesterol, low density lipoproteins and triglycerides) is improved in approximately 70% of patients, with no influence on high-density lipoproteins [16].

Kidney disease

Clinical evidence suggests that weight loss has beneficial effects on renal function [17]. Bariatric surgery improves the glomerular filtration rate (GFR) in patients with pre-existing mild chronic kidney disease (CKD) [18] and reduces albuminuria and/or proteinuria.
in patients with T2DM [19]. A small retrospective study by Navaneethan et al. [18] showed that mean GFR after 6 months of follow-up had improved from 47.9 ml/min/1.73 m² before the procedure to 56.6 ml/min/1.73 m² (p < 0.001) and after 12 months GFR increased to 61.6 ml/min/1.73 m² (p < 0.001). Nevertheless, there is as yet no consensus on the effect of bariatric procedures on renal function, mainly due to difficulties in estimation of GFR in this group of patients (common equations are restricted by body size founders).

Furthermore, bariatric surgery may be associated with acute kidney injury (AKI) and severe electrolyte disturbances, particularly after RYGB and BPD. The etiology of renal failure after these procedures is complex and may include dehydration due to diarrhea or vomiting [20], and intratubular calcium oxalate crystal deposition [21]. Post-bariatric AKI can develop in up to 8.6% of patients, mainly during the first 72 hours after surgery. Significantly, the incidence of AKI after bariatric surgery is much greater than that reported after any other general surgical procedures [22].

**Other disorders**

Obese individuals have an increased prevalence of obstructive sleep apnea (OSA). Almost 70% of patients referred for bariatric surgery suffer from this disorder, and more than 40% fulfill the criteria of severe OSA [23]. Bariatric surgery can produce improvement or even full remission of OSA in nearly 84% of patients (95% CI: 71.8–95.4%) [16], an improvement that is maintained in the long term. The mechanisms are not fully established but probably relate to both weight-loss-dependent effects (such as decreased mechanical force on the neck, upper airway and diaphragm) and weight-loss-independent effect due to metabolic changes (such as bile flow alteration, reduction of gastric size, anatomical rearrangement, vagal manipulation, and enteric gut hormone modulation) [24].

Recent emerging evidence suggests a positive outcome of bariatric surgery on cancer incidence in comparison to obese patients who did not undergo surgery [25]. A recent meta-analysis indicated a more pronounced protective effect of the bariatric procedure in women (HR = 0.58, 95% CI: 0.44–0.77) than in men (HR = 0.97, 95% CI: 0.62–1.52) [25]. Weight loss itself, even without surgical intervention, has been demonstrated to decrease the risk of cancer. The etiology of this effect is complex, and it evolves inter alia from hormonal and inflammatory pathway alteration due to adipose tissue reduction [26].

**Medical management after bariatric surgery**

All patients after bariatric surgery require long-lasting observation for complications of bariatric procedures. Complementary follow-up pathways (surgical, medical, psychological, dietary) should be provided to all patients. Treatment outcome is primarily dependent on patient compliance. Patients should be aware not only of the necessity of a nutritionally adequate diet but also of the need for regular follow-up. They should be encouraged to incorporate moderate aerobic physical activity of at least 150 minutes per week (preferably 300 minutes weekly) [7].

Medical follow-up should begin at least 1 month after bariatric surgery, followed by at least 1 visit every 3 months after the operation in the first post-surgical year, every 6 months in the second year and annually thereafter [8]. Complete blood count, creatinine, liver function tests, glucose and electrolytes should be assessed during each visit. Serum concentration of iron, vitamin B12, vitamin 25(OH)D3, folate, calcium, parathormone and albumin should be performed before every type of surgery, and 6 months, 12 months and annually after RYGB, BPD and bilio-pancreatic diversion with a duodenal switch (BPD-DS) [27]. Optionally, screening for vitamin and trace element deficiency may be conducted (including vitamin B1, A, E, zinc, selenium and copper), but in the case of evidence of a poor diet or vomiting or malaise it should be checked.

**Early and late complications of bariatric surgery**

Post-bariatric complications can be considered as early or late. Early problems involving mainly anastomotic leakage, bleeding and pulmonary embolism are usually managed by the operating team during surgery or in the early post-operative period. The incidence of anastomotic leakage ranges from 0.1 to 5.6% [3], but the mortality rate is high and may reach 50%, and therefore it is considered as the most life-threatening post-bariatric complication. Surgical exploration and treatment is needed if there is any clinical suspicion which may present as tachycardia, tachypnoea, hypoxia, increasing pain, fever or elevation of inflammatory markers [8].

In order to avoid deep vein thrombosis/pulmonary embolism, all bariatric patients should receive subcutaneous low-molecular weight heparin administration after surgery, and post-operatively until they are fully mobile. If possible, they should also be provided with graded compression stockings or intermittent pneumatic leg compression [8]. Late complications of bariatric surgery may be less urgent, but can still pose important health risks to patients. Some of the main issues relate to weight regain prevention,
nutritional management, management of type 2 diabetes mellitus and lipid disorders, bone mineral metabolism and psychological disturbances. Vigilance for late complications from surgery (e.g. stricture) also remains necessary.

**Diabetes mellitus and lipid metabolism management**

In order to minimize the risk of hypoglycemia in T2DM patients, anti-diabetic pharmacotherapy should be adjusted immediately after bariatric surgery. According to the Guidelines of the International Federation for the Surgery of Obesity and the European Association for the Study of Obesity, improvement of T2DM may be considered to have occurred if:

- the post-operative insulin dose is reduced by at least 25% compared with pre-operatively,
- the post-operative oral anti-diabetic treatment dose is reduced by at least 50% compared with pre-operatively,
- there is a post-operative reduction in Hba1c of at least 0.5% within 3 months or it reaches < 7.0% [8].

The Endocrine Society recommends the following postoperative glycemic control targets [27]:

- Hba1c ≤ 7.0% with
- fasting blood glucose ≤ 110 mg/dl and
- postprandial glucose ≤ 180 mg/dl.

Diabetes mellitus and lipid disorder management should be considered concomitantly.

A substantial improvement in the metabolic state may be defined as [9]:

- Hba1c reduced by > 2.0%,
- LDL < 2.3 mmol/l,
- blood pressure < 135/85 mmHg,
- reduced medication from pre-operative state.

T2DM remission has been defined as:

- partial remission – hyperglycemia below diagnostic thresholds for diabetes (Hba1c > 6%, but < 6.5%, fasting plasma glucose [FPG] 100-125 mg/dl) of at least 1-year duration, no active pharmacological therapy or ongoing procedures,
- complete remission – normal glycemic measures (Hba1c normal range [≤ 6%], FPG < 100 mg/dl), at least 1-year duration, no active pharmacological therapy or ongoing procedures,
- prolonged remission – complete remission of at least 5-year duration [8].

If clinical resolution of type 2 diabetes is demonstrated after surgery, anti-diabetic medications should be withdrawn. However, patients must continue capillary blood glucose monitoring according to their pre-operative needs. If further anti-diabetic management is necessary, insulin secretagogues should be discontinued and insulin doses should be adjusted to minimize the risk of hypoglycemia [7]. Metformin therapy might be applied with the dose of 500 mg at the time of discharge and it should be adjusted to glycemia subsequently.

Although there have been studies demonstrating recovery from albuminuria in patients after bariatric surgery, one report showed deterioration of diabetes neuropathy and retinopathy after RYGB [28]. Therefore T2DM patients should be carefully observed on a regular basis for microvascular complications.

**Metabolic bone disease management**

Although not well recognized, obesity and osteoporosis coexist; loss of body mass profoundly influences bone metabolism. Vitamin D and calcium deficiencies with secondary hyperparathyroidism are common findings in extremely obese pre-bariatric surgery patients. Approximately 90% of obese individuals may be at risk of vitamin D deficiency (vitamin D concentration < 30 ng/ml) prior to the bariatric procedure. Parathormone (PTH) levels are positively correlated with BMI, and 25-48% of obese individuals have an elevated PTH concentration [29].

Up to 25% of obese patients who have not undergone bariatric surgery have a pre-existing subclinical calcium deficiency (elevated PTH with normal Ca<sup>2+</sup>) [30]. This constellation of abnormalities predisposes extremely obese patients to low bone mass and osteomalacia even before surgery. Afterwards, as patients lose weight, their PTH levels continue to increase and the 25-hydroxyvitamin D concentration decreases.

Restrictive as well as malabsorptive procedures appear to place patients at high risk of metabolic bone disease as a consequence of restricted oral intake, inadequate calcium and vitamin D supply, and rapid weight loss. Inappropriate supplementation post-operatively results in a significant bone disease 8 weeks to 32 years after surgery [31].

Voluntary weight loss of about 10% leads to bone loss of around 1-2% at all sites [31]. It appears that more than 70% of patients who have had a malabsorptive procedure may develop metabolic bone disease; significant bone resorption becomes evident as soon as 3 months after bariatric surgery independently of the type of the procedure [32]. Although the data regarding the influence of bariatric surgery on bone mineral density are inconsistent, a growing number of studies indicate a bone mineral density (BMD) decline. In a study conducted by Carrasco et al., 12 months after gastric bypass surgery total BMD significantly decreased by 3% [33].

Post-bariatric supplementation should provide 1200-1500 mg of calcium citrate (not calcium carbonate) and 3000 IU of vitamin D in order to prevent metabolic bone disease. However, if vitamin D deficiency below 20 ng/ml develops, the therapeutic dose should provide 7000-10 000 IU per day (depending on body mass) or 50 000 IU per week [34].
Bone mineral density should be assessed before bariatric surgery and monitored annually after the procedure [27]. However, it might be complicated due to the high body mass of bariatric patients and technical capabilities of the dual-energy X-ray absorptiometry (DEXA) table.

Gastroenterological and eating behavior management

Vomiting

Reduced capacity of the gastric pouch after restrictive procedures (30-60 ml) results in significant limitation of the amount of food consumed. Nausea, regurgitation and vomiting are particularly likely when compliance with nutritional recommendations is disregarded. Thirty to 60% of post-bariatric patients report vomiting, mostly within the first few months after surgery, when patients are adapting to the small gastric pouch [27]. Alarming symptoms, such as persistent vomiting, nausea, abdominal pain, diarrhea and constipation, should lead to the careful further assessment of other overlapping disorders such as bacterial overgrowth, ulcer disease, anastomotic complications, and bowel obstruction.

Dumping syndrome

Rapid gastric emptying and early exposure of the small intestine to energy-dense nutrients may trigger a group of symptoms constituting dumping syndrome (DS). Early symptoms comprise gastrointestinal and vasomotor manifestations, while late DS stems from postprandial hypoglycemia [35].

Among other factors contributing to the pathogenesis of the syndrome there is a release of gastrointestinal and pancreatic hormones, such as enteroglucagon, vasoactive intestinal peptide, peptide YY, pancreatic polypeptide and neuropeptide YY [36]. Key symptoms of early DS develop 15-30 minutes after a meal and include:

- gastrointestinal symptoms – abdominal pain, nausea, epigastric fullness, diarrhea, borborygmi,
- vasomotor manifestation – dizziness, flushing, dyspnea, tachycardia, apathy, weakness and syncope [27].

The prevalence of DS ranges between 40 and 76% of patients after RYGB. Although restrictive interventions such as SG should not be expected to exert DS, two prospective studies demonstrated development of symptoms suggestive of dumping syndrome 6-12 months after SG in up to 40% of patients [27,37-39]. Treatment of DS should be started with implementation of nutritional change. Patients should eat at least 3 small, frequent meals and avoid refined-carbohydrate dense food. They should chew small bites of food prior to swallowing, and liquids should not be ingested earlier than 30 minutes after a solid-food meal. Ingestion of protein, fiber and complex carbohydrates should be increased.

Pharmacological intervention includes administration of somatostatin analogues, such as octreotide 50 mg s.c. – given 30 minutes prior to the meal it may improve symptoms in some patients [27]. A novel agent, undergoing phase 2 testing – pasireotide – may become an alternative for the pharmacological treatment of DS [40].

Symptoms of DS usually resolve spontaneously 18-24 months after surgery. Controversially, although considered as a complication, DS may be in fact a desired element of behavior modification. It discourages the intake of energy-dense food and beverages [27]. Nevertheless, it has been shown that better adherence to dietary advice from the very beginning in non-dumpers leads to a greater decrease in BMI at 1 and 2 years of follow-up [37].

Postprandial hypoglycemia

Postprandial hyperinsulinemic hypoglycemia with neuroglycopenic symptoms (such as altered mental status, loss of consciousness) has been observed in some patients after RYGB. It is frequently identified with dumping syndrome, although in distinction to hyperinsulinemic hypoglycemia, DS rarely presents with symptoms of neuroglycopenia [41]. Postprandial hypoglycemia tends to develop usually 2 to 9 years after gastric bypass [41]. Patients presenting neuroglycopenic symptoms, who do not respond to nutritional modification, should be evaluated to differentiate dumping syndrome, insulinoma and non-insulinoma pancreatogenous hypoglycemia syndrome (NIPHS) [42,43]. Noninsulinoma pancreatogenous hypoglycemia syndrome was introduced for the first time by Service et al. in 1999 [42]. Suggested mechanisms have ranged from expansion of beta cell mass (e.g. nesidioblastosis) to alterations in beta cell function (glucagon-like peptide-1 contributes to beta cell proliferation) and non-beta cell related factors (decreased levels of the apoglycemia syndrome was introduced for the first time by Service et al. in 1999 [42]. Suggested mechanisms have ranged from expansion of beta cell mass (e.g. nesidioblastosis) to alterations in beta cell function (glucagon-like peptide-1 contributes to beta cell proliferation) and non-beta cell related factors (decreased levels of the apoglycemia syndrome was introduced for the first time by Service et al. in 1999 [42]. Suggested mechanisms have ranged from expansion of beta cell mass (e.g. nesidioblastosis) to alterations in beta cell function (glucagon-like peptide-1 contributes to beta cell proliferation) and non-beta cell related factors (decreased levels of the apoglycemia syndrome was introduced for the first time by Service et al. in 1999 [42]. Suggested mechanisms have ranged from expansion of beta cell mass (e.g. nesidioblastosis) to alterations in beta cell function (glucagon-like peptide-1 contributes to beta cell proliferation) and non-beta cell related factors (decreased levels of the apoglycemia syndrome was introduced for the first time by Service et al. in 1999 [42]. Suggested mechanisms have ranged from expansion of beta cell mass (e.g. nesidioblastosis) to alterations in beta cell function (glucagon-like peptide-1 contributes to beta cell proliferation) and non-beta cell related factors (decreased levels of the apoglycemia syndrome was introduced for the first time by Service et al. in 1999 [42]. Suggested mechanisms have ranged from expansion of beta cell mass (e.g. nesidioblastosis) to alterations in beta cell function (glucagon-like peptide-1 contributes to beta cell proliferation) and non-beta cell related factors (decreased levels of the apoglycemia syndrome was introduced for the first time by Service et al. in 1999 [42]. Suggested mechanisms have ranged from expansion of beta cell mass (e.g. nesidioblastosis) to alteration...
Management of hepatobiliary complications

Cholelithiasis is a common complication of rapid weight loss, occurring in 13-36% of patients within 6 months after RYGB, but also after SG [44]. Cholecystectomy at the time of bariatric surgery is still a matter of debate. Some specialists suggest performing routine cholecystectomy at the time of gastric bypass, especially considering the technical difficulties in performing endoscopic retrograde cholangiopancreatography after RYGB [44]. However, most surgeons perform cholecystectomy only if the patient is symptomatic [45]. A possible approach is administration of ursodeoxycholic acid (UDA) post-operatively. According to a double blind prospective randomized trial by Sugerman et al. [46] a daily dose of 600 mg UDA is an effective prophylaxis for gallstone formation.

Pharmacotherapy remarks

For the first 4 weeks following the surgery, crushed or liquid medications should be administered in rapid-release, non-enteric-coated formulations to maximize absorption [8]. If drug levels can be measured (e.g. anti-convulsants, lithium) or effects monitored (e.g. thyroid hormone replacement), it may be reasonable to make checks 1-2 months after surgery. For the first 6 months following the RYGB and SG procedure, therapy with proton pump inhibitors is recommended in order to prevent ulceration at the pouch jejunostomy.

Hypoglycemic treatment

Metformin is a first-line drug in obese diabetic patients. Since metformin is absorbed mainly in the proximal part of the small intestine, the question of its post-bariatric surgery pharmacokinetics has been raised. Contrary to the hypothesis that absorption would be significantly impaired in patients after RYGB, the only study conducted to date demonstrated that the absorption and bioavailability of metformin in these patients is increased [47]. Further studies are required in order to establish the clinical significance of this finding.

Antihypertensive agents and statins

The need for antihypertensive drugs, including diuretics, is reduced by around 50% after bariatric surgery [48]. Although antihypertensive drugs of all groups are frequently used in bariatric surgery patients, only studies on the pharmacokinetics of beta blockers (propranolol and atenolol) have been conducted. Due to the changes in pharmacokinetics of propranolol after partial gastrectomy (probably because of its lipophilicity), hydrophilic drugs e.g. atenolol may be preferred, if beta blocker therapy is still necessary [49].

Available evidence shows that bariatric surgery is effective for decreasing the use of statins for dyslipidemia. Post-operatively patients on statin treatment should be re-titrated on the lowest dose possible while monitoring the serum lipids profile [50].

Oral contraceptives

According to the reproductive hormone profile and pregnancy outcomes, fertility status improves rapidly after bariatric surgery [51]. However, women who have undergone a bariatric procedure should be aware of possibly lower efficacy of contraceptives, due to malabsorption and post-operative complications, such as diarrhea and vomiting. Patients should not rely on combined oral contraceptives (COC) and if menstrual (as is the case immediately after bariatric surgery) should consider dual contraception (e.g. condom + COC).

Behavioral and psychological support

Psychological assessment is an essential part of pre-operative evaluation indentifying potential contraindications for bariatric surgery or post-operative risks. Non-stabilized psychotic disorders, severe depression and personality disorders are contraindications for bariatric

<table>
<thead>
<tr>
<th>Criterion element</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Positive Whipple’s triad</td>
<td>• Episodic hypoglycemia&lt;br&gt;• Central nervous system dysfunction temporally related to hypoglycemia (confusion, anxiety, stupor, paralysis, convulsions, coma)&lt;br&gt;• Reversal of these abnormalities by glucose administration</td>
</tr>
<tr>
<td>2. A negative 72-hour fast</td>
<td></td>
</tr>
<tr>
<td>3. Negative observation toward insulinoma</td>
<td>• Negative peri-operative radiographic imaging</td>
</tr>
<tr>
<td>4. Positive calcium stimulation test</td>
<td></td>
</tr>
<tr>
<td>5. Islet hypertrophy or nesidioblastosis</td>
<td>• Nesidioblastosis – β-cell hyperplasia and diffuse proliferation and hypertrophy of islet cells from pancreatic ducts</td>
</tr>
</tbody>
</table>
postoperative psychological care is as vital as other surveillance aspects. A number of studies have shown postoperative improvement in depressive symptoms, self-esteem, health-related quality of life, and body image [54]. However, a lot of patients continue to suffer from emotional disturbances, mainly due to unrealistic pre-surgical expectations concerning weight loss and difficulties associated with the necessity of post-bariatric lifestyle changes. Several studies have reported increased suicide incidence in patients after bariatric surgery, with an estimated suicide rate of 3.9/10 000, compared with 1.0/10 000 in the general population [55]. The most common reason found is depression, but the spectrum of mental disorders linked to suicidal ideation and attempts is wide. A lifetime prevalence of 30% for mood disorders, 23% for substance abuse and 48% for anxiety disorders was revealed in morbidly obese bariatric patients [56]. Difficulties in coping with lifestyle changes, disappointment about failed weight loss or weight regain, and recurrence of obesity-related diseases after initial improvement are additional burdens in this group. According to Tindle et al., 70% of patients who committed suicide did so within 3 years after the bariatric procedure [57]. Therefore, post-bariatric treatment should be provided for as long as the patient demonstrates psychological distress or has difficulties in maintaining behavioral changes and the diet regime [58].

Conclusions

Even though bariatric surgery is the most effective method of achieving long-lasting weight loss and improving metabolic and cardiovascular outcomes in selected patients, not everyone is eligible or meets the criteria for surgery. After all, bariatric surgery should be considered as a method of ultima ratio after exhausting all other medical possibilities. If performed, multidisciplinary surveillance is important for maintaining optimal health of patients in the long term. One of the most important aspects of post-bariatric follow-up is nutritional care and eating behavior modification. Severe nutritional deficits can be avoided after bariatric procedures, provided patients are systematically supplemented with multivitamins and carefully monitored. Similarly, the majority of post-surgical complications may be prevented if patients are aware of the fact that surgical treatment is inseparably associated with lifelong behavioral changes.

Disclosure

Gabriela Handzlik-Orlik was supported by the European Community from the European Social Fund within the DoktoRIS project.

Other authors report no conflict of interest.

References


